MedPath

A 12-week, multi-center,randomized, double-blind, placebo-controlled efficacy and safety study examining seizure frequency of BGG492 capsules administration orally three times daily (TID) as adjunctive treatment in patients with partial onset seizures.

Conditions
refractory partial-onset seizures
MedDRA version: 12.1Level: LLTClassification code 10065336Term: Partial epilepsy
Registration Number
EUCTR2009-017961-52-SK
Lead Sponsor
ovartis Pharma Services AG
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
81
Inclusion Criteria

Key inclusion criteria:
- male or female
- weight sup or equal to 50kg
- have a diagnosis of epilepsy ( For Cohort 1 abnormal EEG more than 2 years prior to screening) with partial seizures with or without secondarily generalizations seizures. For Cohort 2 the abnormal EEG at any time prior to screening.
- have uncontrolled partial seizures
- have at least 4 partial seizures
- have no 28-day seizure-free period during the 8 weeks preceding randomization
- Cohort 1 pstients must be receiving stable treatment with 1 or a maximum of 2 AEDs, whereas Cohort 2 patients must be receiving stable treatment with 1, 2 or 3 AEDs.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Key exclusion criteria:Any of the following seizure conditions:
- Presence of only non-motor simple partial seizures
- Pschogenic seizures within 52 weeks prior to screening
- Absences and/or myoclonic seizures e.g. in the context of primarily generalized epilepsy
- Previous history of Lennox-Gastaut syndrome
- Status epilepticus or seizure clusters where individual seizures cannot be counted according to the judgement of the investigator occuring within 52 weeks prior to randomization

For other criteria, please refer to the Protocol.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath